Clinical trials: HSCT
Graft-Versus-Host Disease, Hematological Malignancies
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).
- Trial name
- NCT01428973
- Testing
- Mycophenolate mofetil, Sirolimus
- Where
- 13 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- University of Liege
Malignancy, Metabolic Disease
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
This study will describe the pharmacokinetic disposition of biologically active rabbit anti-thymocyte globulin (rATG) after a consistent dose of 7.5 mg/kg/course given as part of the conditioning regimen in children undergoing…
- Conditions
- Malignancy, Metabolic Disease, Genetic Disorder
- Trial name
- NCT01135537
- Testing
- Thymoglobulin (rATG)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- The Hospital for Sick Children
Cardio-oncology, Hematopoietic Stem Cell Transplantation
Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity
Hematopoietic stem cell transplantation is an important method for the treatment of hematological diseases and cyclophosphamide is a commonly used chemotherapeutic agent for transplant pretreatment.
- Conditions
- Cardio-oncology, Hematopoietic Stem Cell Transplantation, Cardiotoxicity, Cyclophosphamide
- Trial name
- EIECC (NCT05150080)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Kai Mu
Sickle Cell Disease, Beta Thalassemia-Major
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
This study will evaluate the use of reduced intensity conditioning regimen in patients with high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard immunosuppressive medications, followed by a…
- Trial name
- NCT02435901
- Testing
- alemtuzumab (Campath IH), Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northwell Health
Hematologic Malignancies
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served.
- Trial name
- NCT01203722
- Testing
- Fludarabine, Cytoxan, Total Body Irradiation
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B-cell Acute Lymphoblastic Leukemia
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue.
- Trial name
- NCT05470777
- Testing
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphocytic, Acute, AML
Stem Cell Transplantation for Hematological Malignancies
This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS).
- Conditions
- Leukemia, Lymphocytic, Acute, AML, MDS
- Trial name
- NCT00176839
- Testing
- Stem Cell Transplant, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Thalassemia in Children
Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
The objective of this observational study is to explore the long-term effects of roprastine given to promote platelet implantation in hematopoietic stem cell hemicongruent transplantation in children with thalassemia.
- Trial name
- NCT07003256
- Testing
- Romiplostim
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
This is a prospective observational cohort study of haploidentical transplantation with post-transplant cyclophosphamide for acute leukemias using reduced intensity conditioning for acute myeloid leukemia (AML) and myeloablative…
- Trial name
- NCT02759822
- Testing
- Haploidentical Stem Cell Transplantation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Leonardo Javier Arcuri
HSCT, Respiratory
Assessing Pulmonary Changes in HSCT
This will be an un-blinded, open-label study of children and adults, including those who are being evaluated for or who have undergone HSCT, those with existing respiratory conditions and/or diagnosed gas-exchange impairment, and…
- Conditions
- HSCT, Respiratory, Gas Exchange Impairment
- Trial name
- NCT07823036
- Testing
- Hyperpolarized 129 Xenon
- Where
- United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Graft Versus Host Disease, Bone Marrow Transplantation
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Graft versus host disease (GVHD) is one of the common complications after stem cell transplant. This is a complication, which happens when the new stem cells from the donor attack other cells in the body of the transplant…
- Trial name
- NCT00775632
- Testing
- Alemtuzumab, mycophenolate or cyclosporine and methotrexate
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- University Health Network, Toronto
Leukemia, Lymphoma
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00006252
- Testing
- fludarabine phosphate, Cyclophosphamide, PBSC
- Where
- 19 sites in United States
- Volunteers
- 47 people
- Sponsor
- Cancer and Leukemia Group B
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Cancer
Airway Reactivity in Children Before and After BMT Bone Marrow Transplantation
Background: Stem cell transplantation (SCT) is associated with pulmonary complications and may lead to high morbidity and mortality.
- Trial name
- AHR (NCT00771836)
- Where
- Israel
- Volunteers
- 39 people
- Sponsor
- Rambam Health Care Campus
DOCK8 Deficiency
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Background: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers.
- Trial name
- NCT01176006
- Testing
- Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Lymphoblastic Leukemia, Acute, Childhood;
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
With this protocol the ALL-SZT BFM international study group wants to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated matched donors (MD) is equivalent to the HSCT from matched…
- Trial name
- NCT01423747
- Testing
- VP16, TBI, VP16, ATG
- Where
- 24 sites in Austria, Germany
- Volunteers
- 400 people
- Sponsor
- St. Anna Kinderkrebsforschung
Sickle Cell Disease
Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD
Sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will probably preserve their immune response to vaccinations administered prior to the…
- Trial name
- PROTECT (NCT05200338)
- Testing
- Engerix-B
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Breast Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells.
- Trial name
- NCT00002509
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Temple University
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.